Literature DB >> 29020646

HIV-1 subtype CRF01_AE and B differ in utilization of low levels of CCR5, Maraviroc susceptibility and potential N-glycosylation sites.

Anjali Joshi1, Emily K Cox2, Melina J Sedano2, Erin B Punke2, Raphael Tc Lee3, Sebastian Maurer-Stroh4, Palvinder Kaur5, Oon Tek Ng5, Himanshu Garg6.   

Abstract

HIV subtypes not only predominate in different geographical regions but also differ in key phenotypic characteristics. To determine if genotypic and/or phenotypic differences in the Envelope (Env) glycoprotein can explain subtype related differences, we cloned 37 full length Envs from Subtype B and AE HIV infected individuals from Singapore. Our data demonstrates that CRF01_AE Envs have lower Potential N Glycosylation Sites and higher risk of ×4 development. Phenotypically, CRF01_AE were less infectious than subtype B Envs in cells expressing low levels of CCR5. Moreover, the Maraviroc IC50 was higher for subtype B Envs and correlated with infectivity in low CCR5 expressing cells as well as PNGS. Specifically, the glycosylation site N301 in the V3 loop was seen less frequently in AE subtype and CXCR4 topic viruses. CRF01_AE differs from B subtype in terms of CCR5 usage and Maraviroc susceptibility which may have implications for HIV pathogenesis and virus evolution.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AIDS; CCR5; CD4; CRF01_AE; Envelope; HIV; Maraviroc; PNGS; Subtype B; gp120

Mesh:

Substances:

Year:  2017        PMID: 29020646      PMCID: PMC5653400          DOI: 10.1016/j.virol.2017.09.026

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  77 in total

1.  Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses.

Authors:  Jérémie Prévost; Daria Zoubchenok; Jonathan Richard; Maxime Veillette; Beatriz Pacheco; Mathieu Coutu; Nathalie Brassard; Matthew S Parsons; Kiat Ruxrungtham; Torsak Bunupuradah; Sodsai Tovanabutra; Kwan-Ki Hwang; M Anthony Moody; Barton F Haynes; Mattia Bonsignori; Joseph Sodroski; Daniel E Kaufmann; George M Shaw; Agnès L Chenine; Andrés Finzi
Journal:  J Virol       Date:  2017-03-13       Impact factor: 5.103

2.  HIV ENV glycoprotein-mediated bystander apoptosis depends on expression of the CCR5 co-receptor at the cell surface and ENV fusogenic activity.

Authors:  Anjali Joshi; Alice M Nyakeriga; Revathi Ravi; Himanshu Garg
Journal:  J Biol Chem       Date:  2011-08-22       Impact factor: 5.157

3.  In vivo evolution of human immunodeficiency virus type 1 toward increased pathogenicity through CXCR4-mediated killing of uninfected CD4 T cells.

Authors:  Andreas Jekle; Oliver T Keppler; Erik De Clercq; Dominique Schols; Mark Weinstein; Mark A Goldsmith
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

4.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

5.  HIV type 1 polymerase gene polymorphisms are associated with phenotypic differences in replication capacity and disease progression.

Authors:  Oon Tek Ng; Oliver Laeyendecker; Andrew D Redd; Supriya Munshaw; Mary K Grabowski; Agnes C Paquet; Mark C Evans; Mojgan Haddad; Wei Huang; Merlin L Robb; Steven J Reynolds; Ronald H Gray; Maria J Wawer; David Serwadda; Susan H Eshleman; Thomas C Quinn
Journal:  J Infect Dis       Date:  2013-08-06       Impact factor: 5.226

6.  Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960.

Authors:  Michael Worobey; Marlea Gemmel; Dirk E Teuwen; Tamara Haselkorn; Kevin Kunstman; Michael Bunce; Jean-Jacques Muyembe; Jean-Marie M Kabongo; Raphaël M Kalengayi; Eric Van Marck; M Thomas P Gilbert; Steven M Wolinsky
Journal:  Nature       Date:  2008-10-02       Impact factor: 49.962

7.  MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection.

Authors:  A Karlsson; K Parsmyr; E Sandström; E M Fenyö; J Albert
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

8.  Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain.

Authors:  Piraporn Utachee; Shota Nakamura; Panasda Isarangkura-Na-Ayuthaya; Kenzo Tokunaga; Pathom Sawanpanyalert; Kazuyoshi Ikuta; Wattana Auwanit; Masanori Kameoka
Journal:  J Virol       Date:  2010-02-17       Impact factor: 5.103

9.  Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site.

Authors:  Piraporn Utachee; Panasda Isarangkura-na-ayuthaya; Kenzo Tokunaga; Kazuyoshi Ikuta; Naokazu Takeda; Masanori Kameoka
Journal:  Retrovirology       Date:  2014-04-23       Impact factor: 4.602

Review 10.  Host and Viral Factors in HIV-Mediated Bystander Apoptosis.

Authors:  Himanshu Garg; Anjali Joshi
Journal:  Viruses       Date:  2017-08-22       Impact factor: 5.048

View more
  1 in total

1.  Combination gene therapy for HIV using a conditional suicidal gene with CCR5 knockout.

Authors:  Tugba Mehmetoglu-Gurbuz; Rose Yeh; Himanshu Garg; Anjali Joshi
Journal:  Virol J       Date:  2021-01-30       Impact factor: 4.099

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.